Old and New Anti-obesity Drugs

Overview

Journal J Diabetes Metab Disord

Specialty Endocrinology

Date 2024 Dec 23

PMID 39712336

Authors

Salimeh Dodangeh

Shirin Hasani-Ranjbar

Affiliations

Soon will be listed here.

Abstract

Obesity is a pandemic problem that correlates with a cluster of metabolic factors leading to poor cardiovascular outcomes, morbidity, and an increased risk of overall mortality. It is necessary to approach obesity with a comprehensive treatment plan, which may involve lifestyle modifications (diet, exercise, and behavioral therapy) and pharmacological interventions. This article provides an overview of the mechanisms of action, efficacy, and safety of available long-term anti-obesity drugs and introduces other potential agents under investigation.

References

Kelly M, Loose M, Ronnekleiv O . Opioids hyperpolarize beta-endorphin neurons via mu-receptor activation of a potassium conductance. Neuroendocrinology. 1990; 52(3):268-75. DOI: 10.1159/000125597. View

Willard F, Douros J, Gabe M, Showalter A, Wainscott D, Suter T . Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020; 5(17). PMC: 7526454. DOI: 10.1172/jci.insight.140532. View

Martin C, Redman L, Zhang J, Sanchez M, Anderson C, Smith S . Lorcaserin, a 5-HT(2C) receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure. J Clin Endocrinol Metab. 2010; 96(3):837-45. PMC: 3047218. DOI: 10.1210/jc.2010-1848. View

Lee Y, Shin S, Shigihara T, Hahm E, Liu M, Han J . Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis. Diabetes. 2007; 56(6):1671-9. DOI: 10.2337/db06-1182. View

Guzman C, Zhang X, Liu R, Regev A, Shankar S, Garhyan P . Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes. Diabetes Obes Metab. 2017; 19(11):1521-1528. DOI: 10.1111/dom.12958. View

Jafari-Adli S, Jouyandeh Z, Qorbani M, Soroush A, Larijani B, Hasani-Ranjbar S . Prevalence of obesity and overweight in adults and children in Iran; a systematic review. J Diabetes Metab Disord. 2015; 13(1):121. PMC: 4301060. DOI: 10.1186/s40200-014-0121-2. View

Melson E, Ashraf U, Papamargaritis D, Davies M . What is the pipeline for future medications for obesity?. Int J Obes (Lond). 2024; . DOI: 10.1038/s41366-024-01473-y. View

Muller T, Clemmensen C, Finan B, DiMarchi R, Tschop M . Anti-Obesity Therapy: from Rainbow Pills to Polyagonists. Pharmacol Rev. 2018; 70(4):712-746. DOI: 10.1124/pr.117.014803. View

Wadden T, Chao A, Machineni S, Kushner R, Ard J, Srivastava G . Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023; 29(11):2909-2918. PMC: 10667099. DOI: 10.1038/s41591-023-02597-w. View

10.

Melson E, Miras A, Papamargaritis D . Future therapies for obesity. Clin Med (Lond). 2023; 23(4):337-346. PMC: 10541050. DOI: 10.7861/clinmed.2023-0144. View

11.

Hansen H, Jensen M, Overgaard A, Weikop P, Mikkelsen J . Tesofensine induces appetite suppression and weight loss with reversal of low forebrain dopamine levels in the diet-induced obese rat. Pharmacol Biochem Behav. 2013; 110:265-71. DOI: 10.1016/j.pbb.2013.07.018. View

12.

Mechanick J, Harrell R, Allende-Vigo M, Alvayero C, Arita-Melzer O, Aschner P . TRANSCULTURALIZATION RECOMMENDATIONS FOR DEVELOPING LATIN AMERICAN CLINICAL PRACTICE ALGORITHMS IN ENDOCRINOLOGY--PROCEEDINGS OF THE 2015 PAN-AMERICAN WORKSHOP BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF.... Endocr Pract. 2016; 22(4):476-501. DOI: 10.4158/EP161229.GL. View

13.

Garvey W, Frias J, Jastreboff A, le Roux C, Sattar N, Aizenberg D . Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023; 402(10402):613-626. DOI: 10.1016/S0140-6736(23)01200-X. View

14.

D Axel A, Mikkelsen J, Hansen H . Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat. Neuropsychopharmacology. 2010; 35(7):1464-76. PMC: 3055463. DOI: 10.1038/npp.2010.16. View

15.

Greenway F, Fujioka K, Plodkowski R, Mudaliar S, Guttadauria M, Erickson J . Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010; 376(9741):595-605. DOI: 10.1016/S0140-6736(10)60888-4. View

16.

Gregg E, Shaw J . Global Health Effects of Overweight and Obesity. N Engl J Med. 2017; 377(1):80-81. DOI: 10.1056/NEJMe1706095. View

17.

Abdel-Malek M, Yang L, Miras A . Pharmacotherapy for chronic obesity management: a look into the future. Intern Emerg Med. 2023; 18(4):1019-1030. PMC: 10326094. DOI: 10.1007/s11739-023-03237-4. View

18.

Pradhan R, Montastruc F, Rousseau V, Patorno E, Azoulay L . Exendin-based glucagon-like peptide-1 receptor agonists and anaphylactic reactions: a pharmacovigilance analysis. Lancet Diabetes Endocrinol. 2019; 8(1):13-14. DOI: 10.1016/S2213-8587(19)30382-1. View

19.

Lambson J, Flegal S, Johnson A . Administration errors of compounded semaglutide reported to a poison control center-Case series. J Am Pharm Assoc (2003). 2023; 63(5):1643-1645. DOI: 10.1016/j.japh.2023.06.017. View

20.

Jakubowska A, le Roux C, Viljoen A . The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update. Endocrinol Metab (Seoul). 2024; 39(1):12-22. PMC: 10901658. DOI: 10.3803/EnM.2024.1942. View